Chief Philanthropy Officer
Geisinger Health System, Danville PA
Nancy Lawton-Kluck’s mission is to empower positive change through philanthropy. As such, she is focused on strategically aligning visionaries and philanthropists with opportunities to create sustainable solutions to individual and population health issues that can be scaled nationally and globally. Experience in engaging multiple community stakeholders towards these positive solutions
Examples of areas of impact include creating the best patient experience, eliminating food insecurity and preventable chronic disease as well as leveraging genomics to change the future of healthcare delivery.
Nancy is familiar with payment models, bundles, managed care, population health, public policy, health information exchanges and innovations in patient care. Ms. Lawton-Kluck has Proven experience in extramural funding including Federal (such as CMMI and HRSA), State (RACP and Local Share/Casino), National and Family Foundations, Contracts, and Corporate and Individual Philanthropy.
She has experience in hiring and strategically deploying staff and outside consultants, managing over $100 million in Foundation funds, non-profit funding, contract negotiations, development of case materials and other communication pieces, campaign planning, budgets and financial reporting.
For the fifteen years previous to Geisinger, she was fully licensed as a Registered Investment Adviser and Registered Principal. In this role, managed $35 million in assets, and specialized in estate, wealth and retirement planning.
Dr. Michael Murray
Director of Clinical Genomics
Genomic Medicine Institute | Geisinger Health System
Transforming Disease Prevention with GenomeFIRST
Dr. Mike Murray is board certified in Internal Medicine and Medical Genetics and he joined Geisinger Health System as the director of clinical genomics over four years ago after serving on the faculty at Harvard Medical School and as the clinical chief of genetics at Brigham and Women’s Hospital in Boston for nine years.
Mike earned his medical degree at Penn State Hershey, and went on to do additional training at Cleveland Clinic, University of Pennsylvania, and Harvard Medical School.
At Geisinger he is leading the GenomeFIRST return of results program for the over 150,000 patient participants who undergo Genomic Sequencing as part of the MyCode Community Health Initiative. This project builds on the collaboration between Geisinger and Regeneron Pharmaceuticals, but is funded outside of that research collaboration through internal Geisinger support, external grants, and generous donations.
The GenomeFIRST return of results program expects to deliver important risk information based on genetic sequence back to between 3-4% of MyCode participants in its initial phase. These risks primarily fall into the categories of either risk for cancer or cardiovascular disease. Geisinger is the first institution in the world to build the necessary infrastructure at the scale needed to deliver this kind of genomic results to this many patients and their providers, and to then assist the patients in getting their at-risk family members tested too. This program is expected to help define a best practice model for doing this new 21st century approach to care within healthcare systems everywhere.
Mike was one of the principal investigators on the Boston-based MedSeq project, and is an investigator in both the ClinGen and eMERGE project. He is also the lead editor of a genomics textbook for practicing clinicians, “Clinical Genomics: Practical Applications for Adult Patient Care” (McGraw Hill 2014 ).
Dr. Stephen Dahmer
Chief Medical Officer
Cannabinoid Based Medicines Role in the Treatment of Chronic Pain: Harm Reduction Evidence-Based Compassionate Care
Stephen M. Dahmer is the Chief Medical Officer of Pennsylvania Medical Solutions and has been pivotal in the implementation of patient-centered manufacturing, processing and dispensary systems in New York and Minnesota as the Chief Medical Officer for Vireo Health. He is a board-certified family doctor and a fellow of the Arizona Center for Integrative Medicine. Prior to starting full time work for Vireo Health of New York, Dr. Dahmer was most recently Assistant Clinical Professor of Family Medicine and Community Health at the Icahn School of Medicine at Mount Sinai, where he worked for seven years.
Dr. Dahmer has been pivotal in the evolution of the “Vireo Spectrum” of cannabis extract based medicines that find utility in a wide array of medical illness. Through direct patient experience across multiple states, Dr. Dahmer has developed substantial expertise in cannabis extracts across multiple cannabinoid ratios and delivery modalities including oral solutions, topical treatments, oils for vaporization and capsules.
Dr. Dahmer graduated from the University of Wisconsin – School of Medicine; Madison, WI and obtained his doctor of medicine in 2003, Dr. Dahmer graduated from the University of Wisconsin with a BS in Zoology and Spanish.
Dr. Kent Kester
Sanofi Pasteur, Swiftwater PA
Vaccines & Public Health: A Perspective
Dr. Kent Kester is currently Vice President and Head, Translational Science and Biomarkers at Sanofi Pasteur. During a 24-year career in the US Army, he worked extensively in clinical vaccine development and led multiple research platforms at the Walter Reed Army Institute of Research (WRAIR), the U.S. Department of Defense’s largest and most diverse biomedical research laboratory, an institution he later led as its Commander/Director. His final military assignment was as the Associate Dean for Clinical Research in the School of Medicine at the Uniformed Services University of the Health Sciences (USUHS). Dr. Kester holds an undergraduate degree from Bucknell University and an M.D. from Jefferson Medical College. He completed his internship and residency in internal medicine at the University of Maryland and a fellowship in infectious diseases at the Walter Reed Army Medical Center. A malaria vaccine researcher with over 70 scientific manuscripts and book chapters, Dr. Kester has played a major role in the development of the malaria vaccine candidate known as RTS,S. Currently a member of the US Government Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria, he previously chaired the Steering Committee of the NIAID/USUHS Infectious Disease Clinical Research Program, and has served as a member of the FDA Vaccines & Related Biologics Products Advisory Committee (VRBPAC), the NIAID Advisory Council, and the CDC Office of Infectious Diseases Board of Scientific Counselors. Board-certified in both internal medicine and infectious diseases, he holds faculty appointments at USUHS and the University of Maryland; and is a fellow of the American College of Physicians, the Infectious Disease Society of America, and the American Society of Tropical Medicine and Hygiene.